Advanced search    

Search: authors:"David Preiss"

11 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating enzyme of hepatic origin that plays a key role in LDL receptor turnover. Genetic studies have confirmed that individuals with gain-of-function PCSK9 mutations have increased PCSK9 activity, elevated LDL-cholesterol levels and a severe form of familial hypercholesterolaemia. Those with variants leading to...

The Role of Emerging Risk Factors in Cardiovascular Outcomes

-associated risk and sufficiently large trials of interventions which modify mineral bone disease biomarkers are Ben Lacey, William G. Herrington and David Preiss would like to share first authorship; Sarah

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30–40% reductions in heart failure hospitalisation (HFH) and cardiovascular and all-cause deaths in patients treated with empagliflozin were highly impressive and unexpected. In this review, we discuss briefly why...

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

. Jacobson: consulting fees from Merck and Co, Amarin, AstraZeneca, and Regeneron/Sanofi-Aventis. David Preiss: consulting fees/honoraria from Sanofi in previous academic position. Ricardo Dent, Ian Bridges

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Background Hypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients. Aldosterone excess is a risk factor for progression of kidney disease. Hyperkalaemia is a concern with the use of mineralocorticoid receptor antagonists. We aimed to...

Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up

Aims/hypothesis Insulin resistance is commonly proposed as a precursor to both type 2 diabetes and cardiovascular disease (CVD), yet few studies have directly compared insulin resistance with both outcomes simultaneously and determined whether associations with each outcome differ in strength or are comparable. We assessed the association of fasting insulin and HOMA-IR with...

Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

DAVID PREISS MRCP SOFIA ZETTERSTRAND PHD JOHN J.V. MCMURRAY JAN O STERGREN ERIC L. MICHELSON CHRISTOPHER B. GRANGER SALIM YUSUF MB BS DPHIL KARL SWEDBERG PHD C a r d i o v a s c u l a r a n d